CRISPR-Cas9 Mediated Gene-Silencing of the Mutant Huntingtin Gene in an In Vitro Model of Huntington's Disease

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2017 Apr 4

PMID 28368337

Citations 41

Authors

Nivya Kolli

Ming Lu

Panchanan Maiti

Julien Rossignol

Gray L Dunbar

Affiliations

Soon will be listed here.

Abstract

Huntington's disease (HD) is a fatal neurodegenerative genetic disease characterized by a loss of neurons in the striatum. It is caused by a mutation in the Huntingtin gene () that codes for the protein huntingtin (HTT). The mutant Huntingtin gene (m) contains extra poly-glutamine (CAG) repeats from which the translated mutant huntingtin proteins (mHTT) undergo inappropriate post-translational modifications, conferring a toxic gain of function, in addition to its non-functional property. In order to curb the production of the mHTT, we have constructed two CRISPR (clustered regularly interspaced short palindromic repeat)-Cas9 (CRISPR associate protein) plasmids, among which one nicks the DNA at untranslated region upstream to the open reading frame (uORF), and the other nicks the DNA at exon1-intron boundary. The primary goal of this study was to apply this plasmid into mesenchymal stem cells (MSCs) extracted from the bone-marrow of YAC128 mice, which carries the transgene for HD. Our results suggest that the disruption of uORF through CRISPR-Cas9 influences the translation of mHTT negatively and, to a lesser extent, disrupts the exon1-intron boundary, which affects the translation of the mHTT. These findings also revealed the pattern of the nucleotide addition or deletion at the site of the DNA-nick in this model.

Citing Articles

Global huntingtin knockout in adult mice leads to fatal neurodegeneration that spares the pancreas.

Bragg R, Mathews E, Grindeland A, Cantle J, Howland D, Vogt T Life Sci Alliance. 2024; 7(9).

PMID: 39054288 PMC: 11272958. DOI: 10.26508/lsa.202402571.

Neuroepigenetic Editing.

Hamilton P, Lim C, Nestler E, Heller E Methods Mol Biol. 2024; 2842:129-152.

PMID: 39012593 PMC: 11520296. DOI: 10.1007/978-1-0716-4051-7_6.

Gene editing therapy for cardiovascular diseases.

Wu X, Yang J, Zhang J, Song Y MedComm (2020). 2024; 5(7):e639.

PMID: 38974714 PMC: 11224995. DOI: 10.1002/mco2.639.

Reviewing the Structure-Function Paradigm in Polyglutamine Disorders: A Synergistic Perspective on Theoretical and Experimental Approaches.

Moldovean-Cioroianu N Int J Mol Sci. 2024; 25(12).

PMID: 38928495 PMC: 11204371. DOI: 10.3390/ijms25126789.

In vivo and ex vivo gene therapy for neurodegenerative diseases: a promise for disease modification.

Ebrahimi P, Davoudi E, Sadeghian R, Zadeh A, Razmi E, Heidari R Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(10):7501-7530.

PMID: 38775852 DOI: 10.1007/s00210-024-03141-4.

References

Cattaneo E . Dysfunction of wild-type huntingtin in Huntington disease. News Physiol Sci. 2003; 18:34-7. DOI: 10.1152/nips.01410.2002. View

Capetian P, Dobrossy M, Winkler C, Prinz M, Nikkhah G . To be or not to be accepted: the role of immunogenicity of neural stem cells following transplantation into the brain in animal and human studies. Semin Immunopathol. 2011; 33(6):619-26. DOI: 10.1007/s00281-011-0272-x. View

DiFiglia M, Sena-Esteves M, Chase K, Sapp E, Pfister E, Sass M . Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A. 2007; 104(43):17204-9. PMC: 2040405. DOI: 10.1073/pnas.0708285104. View

Bae S, Kweon J, Kim H, Kim J . Microhomology-based choice of Cas9 nuclease target sites. Nat Methods. 2014; 11(7):705-6. DOI: 10.1038/nmeth.3015. View

Drouet V, Perrin V, Hassig R, Dufour N, Auregan G, Alves S . Sustained effects of nonallele-specific Huntingtin silencing. Ann Neurol. 2009; 65(3):276-85. DOI: 10.1002/ana.21569. View

Ambrose C, Duyao M, Barnes G, Bates G, Lin C, Srinidhi J . Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeat. Somat Cell Mol Genet. 1994; 20(1):27-38. DOI: 10.1007/BF02257483. View

Bartlett D, Davis M . Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res. 2006; 34(1):322-33. PMC: 1331994. DOI: 10.1093/nar/gkj439. View

Xu X, Tay Y, Sim B, Yoon S, Huang Y, Ooi J . Reversal of Phenotypic Abnormalities by CRISPR/Cas9-Mediated Gene Correction in Huntington Disease Patient-Derived Induced Pluripotent Stem Cells. Stem Cell Reports. 2017; 8(3):619-633. PMC: 5355646. DOI: 10.1016/j.stemcr.2017.01.022. View

Gaj T, Gersbach C, Barbas 3rd C . ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 2013; 31(7):397-405. PMC: 3694601. DOI: 10.1016/j.tibtech.2013.04.004. View

10.

Nethercott H, Brick D, Schwartz P . Derivation of induced pluripotent stem cells by lentiviral transduction. Methods Mol Biol. 2011; 767:67-85. PMC: 3695815. DOI: 10.1007/978-1-61779-201-4_6. View

11.

Jeon I, Lee N, Li J, Park I, Park K, Moon J . Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells. Stem Cells. 2012; 30(9):2054-62. DOI: 10.1002/stem.1135. View

12.

Zhang Y, Engelman J, Friedlander R . Allele-specific silencing of mutant Huntington's disease gene. J Neurochem. 2008; 108(1):82-90. PMC: 3166352. DOI: 10.1111/j.1471-4159.2008.05734.x. View

13.

Persichetti F, Carlee L, Faber P, McNeil S, Ambrose C, Srinidhi J . Differential expression of normal and mutant Huntington's disease gene alleles. Neurobiol Dis. 1996; 3(3):183-90. DOI: 10.1006/nbdi.1996.0018. View

14.

Langbehn D, Brinkman R, Falush D, Paulsen J, Hayden M . A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet. 2004; 65(4):267-77. DOI: 10.1111/j.1399-0004.2004.00241.x. View

15.

Doudna J, Charpentier E . Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014; 346(6213):1258096. DOI: 10.1126/science.1258096. View

16.

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

17.

Mojica F, Diez-Villasenor C, Soria E, Juez G . Biological significance of a family of regularly spaced repeats in the genomes of Archaea, Bacteria and mitochondria. Mol Microbiol. 2000; 36(1):244-6. DOI: 10.1046/j.1365-2958.2000.01838.x. View

18.

Zuccato C, Valenza M, Cattaneo E . Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev. 2010; 90(3):905-81. DOI: 10.1152/physrev.00041.2009. View

19.

Kozak M . Effects of intercistronic length on the efficiency of reinitiation by eucaryotic ribosomes. Mol Cell Biol. 1987; 7(10):3438-45. PMC: 367994. DOI: 10.1128/mcb.7.10.3438-3445.1987. View

20.

StrauB A, Lahaye T . Zinc fingers, TAL effectors, or Cas9-based DNA binding proteins: what's best for targeting desired genome loci?. Mol Plant. 2013; 6(5):1384-7. DOI: 10.1093/mp/sst075. View